Evaluation of ZD1839 [gefitinib] (NSC 715055) for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II.
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2012
At a glance
- Drugs Gefitinib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 01 Dec 2007 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2005 New trial record.